CXCL13 Levels Indicate Treatment Responsiveness to Fingolimod in MS Patients

Autor:	Canan Ulusoy, Murat Kürtüncü, Zerrin Karaaslan, Recai Turkoglu, Erdem Tüzün, Halil İbrahim Akçay, Mefkure Eraksoy, Vuslat Yilmaz, Tuncay Gündüz, Burcu Altunrende
Rok vydání:	2021
Předmět:	Oncology medicine.medical_specialty Multiple Sclerosis Fingolimod Hydrochloride business.industry Chemokine CXCL13 Fingolimod Neurology Internal medicine medicine Humans Neurology (clinical) CXCL13 business Immunosuppressive Agents medicine.drug
Zdroj:	European Neurology. 85:69-71
ISSN:	1421-9913 0014-3022
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::499303b20c9f31288a757f7059bf124d https://doi.org/10.1159/000517770 Zobrazit plný text záznamu